Fundraising Fox

Prothena

NASDAQ: PRTA

Dun Laoghaire, Co. Dublin, US · Ireland corporation · 1 known investors

prothena.com ↗

Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins. The company leverages its scientific legacy from Athena Neurosciences and collaborates with academic and industry partners to advance its pipeline of novel therapeutic candidates.

Biotechin /prothena_biosciences_inc@prothenacorp

Founders & leadership

RT
Richard T. CollierDirector
TB
Tran B. NguyenExecutive Officer
AW
Arthur W. HomanExecutive Officer
LG
Lars G. Eckman, M.D., Ph.D.Director
DJ
Dennis J. SelkoeDirector
KL
Karin L. WalkerExecutive Officer
TN
Tara Nickerson, Ph.D.Executive Officer
WM
Wagner M. Zago, Ph.D.Executive Officer
CS
Christopher S. Henney, Ph.D., D.Sc.Director
CD
Carol D. KarpExecutive Officer
SM
Shane M. CookeDirector
AO
Anders O. Harfstrand, M.D., Ph.D.Director

Investors · 1

Sofinnova VenturesMenlo Park · $100K – $15M

Reported raises · per SEC filings

Form D private placements
▶$50MraisedMar 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard T. CollierDirector
  • Tran B. NguyenExecutive Officer
  • Arthur W. HomanExecutive Officer
  • Lars G. Eckman, M.D., Ph.D.Director
  • Dennis J. SelkoeDirector
  • Karin L. WalkerExecutive Officer
  • Tara Nickerson, Ph.D.Executive Officer
  • Wagner M. Zago, Ph.D.Executive Officer
  • Christopher S. Henney, Ph.D., D.Sc.Director
  • Carol D. KarpExecutive Officer
  • Shane M. CookeDirector
  • Anders O. Harfstrand, M.D., Ph.D.Director
  • Gene G. Kinney, Ph.D.Executive Officer, Director
Offering amount
$50M
Amount sold
$50M
First sale
Mar 2018
Incorporated
Corporation, Ireland
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news